Candel Therapeutics (CADL) Free Cash Flow (2020 - 2025)
Candel Therapeutics recorded quarterly Free Cash Flow of -$10.5 million in Q4 2025, down 1.16% quarter-over-quarter from -$10.4 million in Q3 2025, and down 80.57% year-over-year from -$54.2 million in Q4 2024.
Candel Therapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$10.5 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 80.57% year-over-year to -$10.5 million; the TTM figure through Dec 2025 stood at -$38.4 million (down 42.18% YoY), while the FY2025 annual figure was -$38.4 million, down 42.18% from the prior year.
- Free Cash Flow came in at -$10.5 million for Q4 2025 at Candel Therapeutics, down from -$10.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$3.5 million in Q2 2021 to a low of -$10.9 million in Q1 2023.
- A 5-year average of -$7.8 million and a median of -$7.5 million in 2021 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 470.56% in 2021 and grew 26.35% in 2024, its largest moves.
- Candel Therapeutics' Free Cash Flow stood at -$5.7 million in 2021, then declined by 16.56% to -$6.7 million in 2022, then fell by 11.59% to -$7.5 million in 2023, then advanced by 21.98% to -$5.8 million in 2024, then tumbled by 80.57% to -$10.5 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$10.5 million, -$10.4 million, and -$8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -10.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.52 Mn |
| Dec 31, 2025 | -10.52 Mn |
| Sep 30, 2025 | -10.40 Mn |
| Sep 30, 2025 | -10.40 Mn |
| Jun 30, 2025 | -8.89 Mn |
| Jun 30, 2025 | -8.89 Mn |
| Mar 31, 2025 | -8.63 Mn |
| Mar 31, 2025 | -8.63 Mn |
| Dec 31, 2024 | -5.83 Mn |
| Dec 31, 2024 | -5.83 Mn |
| Sep 30, 2024 | -6.56 Mn |
| Sep 30, 2024 | -6.56 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -8.45 Mn |
| Mar 31, 2024 | -8.45 Mn |
| Dec 31, 2023 | -7.47 Mn |
| Dec 31, 2023 | -7.47 Mn |
| Sep 30, 2023 | -8.91 Mn |
| Sep 30, 2023 | -8.91 Mn |
| Jun 30, 2023 | -7.44 Mn |
| Jun 30, 2023 | -7.44 Mn |
| Mar 31, 2023 | -10.89 Mn |
| Mar 31, 2023 | -10.89 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -8.84 Mn |
| Sep 30, 2022 | -8.84 Mn |
| Jun 30, 2022 | -7.48 Mn |
| Jun 30, 2022 | -7.48 Mn |
| Mar 31, 2022 | -8.47 Mn |
| Mar 31, 2022 | -8.47 Mn |
| Dec 31, 2021 | -5.74 Mn |
| Dec 31, 2021 | -5.74 Mn |
| Sep 30, 2021 | -7.29 Mn |
| Sep 30, 2021 | -7.29 Mn |
| Jun 30, 2021 | -3.55 Mn |
| Jun 30, 2021 | -3.55 Mn |
| Mar 31, 2021 | -7.48 Mn |
| Mar 31, 2021 | -7.48 Mn |
| Dec 31, 2020 | -4.82 Mn |
| Dec 31, 2020 | -4.82 Mn |
| Sep 30, 2020 | -1.28 Mn |
| Sep 30, 2020 | -1.28 Mn |